Dynavax Technologies Cash on Hand 2010-2022 | DVAX
Dynavax Technologies cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Dynavax Technologies Annual Cash on Hand
(Millions of US $) |
| 2021 |
$546 |
| 2020 |
$165 |
| 2019 |
$151 |
| 2018 |
$146 |
| 2017 |
$192 |
| 2016 |
$81 |
| 2015 |
$196 |
| 2014 |
$123 |
| 2013 |
$189 |
| 2012 |
$125 |
| 2011 |
$114 |
| 2010 |
$72 |
| 2009 |
$37 |
Dynavax Technologies Quarterly Cash on Hand
(Millions of US $) |
| 2022-03-31 |
$503 |
| 2021-12-31 |
$546 |
| 2021-09-30 |
$414 |
| 2021-06-30 |
$346 |
| 2021-03-31 |
$233 |
| 2020-12-31 |
$165 |
| 2020-09-30 |
$177 |
| 2020-06-30 |
$201 |
| 2020-03-31 |
$130 |
| 2019-12-31 |
$151 |
| 2019-09-30 |
$175 |
| 2019-06-30 |
$140 |
| 2019-03-31 |
$183 |
| 2018-12-31 |
$146 |
| 2018-09-30 |
$180 |
| 2018-06-30 |
$216 |
| 2018-03-31 |
$251 |
| 2017-12-31 |
$192 |
| 2017-09-30 |
$192 |
| 2017-06-30 |
$127 |
| 2017-03-31 |
$85 |
| 2016-12-31 |
$81 |
| 2016-09-30 |
$110 |
| 2016-06-30 |
$139 |
| 2016-03-31 |
$167 |
| 2015-12-31 |
$196 |
| 2015-09-30 |
$221 |
| 2015-06-30 |
$93 |
| 2015-03-31 |
$98 |
| 2014-12-31 |
$123 |
| 2014-09-30 |
$131 |
| 2014-06-30 |
$154 |
| 2014-03-31 |
$178 |
| 2013-12-31 |
$189 |
| 2013-09-30 |
$76 |
| 2013-06-30 |
$89 |
| 2013-03-31 |
$105 |
| 2012-12-31 |
$125 |
| 2012-09-30 |
$148 |
| 2012-06-30 |
$160 |
| 2012-03-31 |
$107 |
| 2011-12-31 |
$114 |
| 2011-09-30 |
$53 |
| 2011-06-30 |
$62 |
| 2011-03-31 |
$53 |
| 2010-12-31 |
$72 |
| 2010-09-30 |
$48 |
| 2010-06-30 |
$58 |
| 2010-03-31 |
$31 |
| 2009-12-31 |
$37 |
| 2009-09-30 |
$47 |
| 2009-06-30 |
$54 |
| 2009-03-31 |
$61 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.637B |
$0.439B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
